In a significant milestone for medical robotics, Lithuania-based Sentante has officially secured the CE mark for its pioneering endovascular robotic surgery platform. This regulatory approval paves the way for the commercial deployment of its teleoperated system across Europe, marking a shift toward the normalization of remote, high-precision vascular interventions. As healthcare systems grapple with specialist shortages and the demand for rapid, high-quality care, Sentante’s entry into the market offers a transformative approach to treating complex vascular conditions.
The Technological Leap: Precision at a Distance
At the heart of Sentante’s innovation is a sophisticated teleoperation framework designed to bridge the gap between physical distance and surgical precision. The platform allows endovascular surgeons to perform intricate procedures—such as balloon angioplasty and stent delivery—from a remote workstation, miles away from the operating room (OR).
The workstation serves as the surgeon’s cockpit, featuring a highly intuitive interface equipped with haptic feedback wires. This tactile response is crucial; it mimics the sensation of physical contact with blood vessels, allowing the clinician to “feel” the resistance and feedback that would typically be experienced during a traditional manual procedure. Complementing this is a high-definition, low-latency visualization system that provides a real-time, 360-degree view of the OR, ensuring that the surgeon maintains complete situational awareness despite the physical separation.
By digitizing the surgical process, Sentante’s platform aims to reduce surgeon exposure to radiation, minimize the physical fatigue associated with wearing heavy lead aprons, and increase the availability of specialized vascular care in underserved regions.
Chronology: From Concept to Clinical Reality
The path to CE mark approval has been a rigorous, multi-year journey defined by iterative development and clinical validation.
Early Development Phase: Sentante focused on the integration of haptic feedback and real-time remote connectivity, ensuring that the platform met the stringent requirements for safety and latency necessitated by vascular surgery.
July 2024 – The ESSENTIAL Study: A pivotal moment occurred with the commencement of the ESSENTIAL study (NCT06537947). This clinical trial served as the bedrock for the company’s regulatory filing. Conducted at the Paula Stradiņš Clinical University Hospital in Riga, Latvia, the study saw the world’s first-in-human procedures using the robotic system.
September 2025 – FDA Recognition: Before the European regulatory milestone, Sentante gained significant international traction when the US Food and Drug Administration (FDA) granted breakthrough device designation to the company’s remote stroke system. This system is specifically designed for the removal of thrombus from intracranial vessels, addressing a critical need in acute ischemic stroke treatment. Furthermore, the system was accepted into the FDA’s Total Product Life Cycle (TAP) Advisory Program, highlighting its potential to impact patient outcomes significantly.
Mid-2026 – CE Mark Achievement: With the successful accumulation of clinical data from the ESSENTIAL study, Sentante received its CE mark, officially authorizing the commercial sale of the endovascular platform within the European Economic Area.
Clinical Validation: The ESSENTIAL Study Data
The regulatory success of the Sentante platform is rooted in the success of the ESSENTIAL study. Principal Investigator Professor Dainis Krievins, a leading expert in vascular and endovascular surgery, oversaw the first-in-human procedures, which demonstrated that the robotic system could match, and in some cases exceed, the precision of manual surgical techniques.
According to the trial data, the system successfully facilitated complex peripheral interventions, demonstrating high levels of maneuverability and stability. Feedback from the surgical team emphasized that the latency of the remote command-and-control system was negligible, allowing for seamless integration into the standard OR workflow. The success of these initial cases proved that the robotic arm could reliably navigate complex vascular anatomies, successfully deploying stents and balloons without adverse events, thereby confirming the safety and effectiveness profile required for the CE mark.
Official Perspectives: CEO and Clinical Leadership
The achievement of the CE mark represents a culmination of years of intense R&D. Edvardas Satkauskas, CEO of Sentante, reflected on the milestone as a turning point for the company:
"Achieving the CE mark is not only a validation of our technology, but also of the rigorous work undertaken by our team to meet the highest regulatory standards. We are now positioned to move decisively into commercialisation and begin delivering real impact for clinicians and patients. Our focus has always been on creating a system that surgeons trust, and this regulatory clearance is the ultimate proof of that trust."
From the clinical side, the perspective remains focused on the patient-centric benefits. Professor Krievins, who conducted the first procedures, noted that the “precision and performance” of the robot were exemplary. By enabling surgeons to operate from a distance, the system effectively democratizes access to expert-level care, allowing a patient in a rural or smaller regional hospital to be operated on by a top-tier specialist based in a major metropolitan center.
Strategic Implications: Scaling for Europe and Beyond
With the CE mark secured, Sentante is shifting its focus toward a structured commercial rollout. The company’s immediate objective is the establishment of strategic partnerships with leading hospitals and healthcare providers throughout Europe.
Integration into Routine Clinical Practice
The transition from experimental tool to routine clinical practice requires more than just hardware. Sentante is investing heavily in clinician training programs. The company recognizes that the shift to robotic-assisted endovascular surgery requires a fundamental change in how surgeons interact with their instruments. By building robust training modules, Sentante aims to lower the barrier to entry for vascular surgeons across the continent.
Advancing the Product Pipeline
Beyond the current endovascular platform, Sentante is not resting on its laurels. The company has explicitly stated its intention to continue expanding its product pipeline, with a particular focus on the remote stroke system that recently received FDA breakthrough designation. By focusing on both peripheral vascular health and acute neurovascular interventions, Sentante is positioning itself as a comprehensive provider of remote surgical solutions.
The Global Competitive Landscape
Sentante enters a growing market segment. According to recent GlobalData analysis, the global robotic surgery market is projected to reach approximately $17.3 billion by 2035. This market is becoming increasingly competitive, with companies like Sovato and Microbot Medical also pushing the boundaries of remote telesurgery.
However, Sentante distinguishes itself through its specific focus on haptic feedback and its proactive engagement with both European and American regulatory bodies. While competitors may focus on automation or AI-assisted guidance, Sentante’s core value proposition remains the human-in-the-loop model, ensuring that the surgeon’s expertise remains the primary driver of the procedure while the technology serves as a high-fidelity extension of their hands.
Future Outlook: A New Paradigm for Healthcare
The implications of Sentante’s technology extend far beyond individual procedures. By successfully navigating the regulatory hurdles in both the US and Europe, Sentante is helping to set the standard for what a remote robotic surgery system should look like.
The future of healthcare is increasingly digital, and the ability to perform life-saving vascular interventions remotely is no longer a futuristic concept—it is a present-day reality. As Sentante begins its commercial journey, the healthcare industry will be watching closely to see how effectively these systems can be integrated into existing hospital infrastructures.
If the company succeeds in its goal of making this technology a staple of routine clinical practice, it will likely trigger a ripple effect in medical education, hospital staffing models, and patient access protocols. The era of the "remote specialist" has arrived, and with the CE mark in its pocket, Sentante is leading the charge, proving that when it comes to saving lives, distance should no longer be a barrier.
